Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).

@article{Rummel2017PreferenceFS,
  title={Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).},
  author={Mathias Johannes Rummel and Taeseob Kim and Franco Aversa and W. E. Brugger and Enrico Capochiani and Caterina Plenteda and Francesca Re and Peter C. Trask and Stuart A Osborne and Rodney Smith and Andrew Grigg},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2017},
  volume={28 4},
  pages={836-842}
}
Background The aim of this study was to evaluate patient preference and satisfaction for the subcutaneous (s.c.) versus intravenous (i.v.) formulation of rituximab given with chemotherapy in previously untreated patients with CD20+ diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Patients and methods Patients received eight cycles of rituximab according to 2 schedules: Arm A received 1 cycle rituximab i.v. (375 mg/m2) and 3 cycles rituximab s.c. (1400 mg) then 4 cycles… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS
7 Citations
16 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Subcutaneous versus intravenous rituximab in combination with CHOP for previously untreated diffuse large B-cell lymphoma: efficacy and safety results from the phase IIIB MABEASE study

  • P Lugtenburg, A Rueda, I Avivi
  • Haematologica
  • 2015
Highly Influential
13 Excerpts

Patient preference with subcutaneous vs intravenous rituximab combined with CHOP for untreated diffuse large B-cell lymphoma: results from the phase IIIb MABEASE study

  • P Lugtenburg, A Rueda, I Avivi
  • Hematol Oncol
  • 2015
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…